Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TrivarX Limited ( (AU:TRI) ) has issued an update.
TrivarX advanced development of its Stabl-Im brain imaging technology during the March quarter, refining Phase 1 clinical trial design, progressing manufacturing validation, and initiating early regulatory planning in the U.S. and Europe. The company also engaged leading contract research organisations and continued building its stable isotope imaging platform, targeting earlier, non-invasive detection of tumour activity beyond the limitations of conventional MRI.
These technical and clinical preparations are supported by a strong cash position of $2.91 million and a strategic refocus on commercialisation, including increased Board involvement and strengthened governance. Post quarter, the appointment of radiopharmaceutical specialist Dr Danielle Meyrick as CEO is expected to accelerate clinical execution and commercial development, potentially improving TrivarX’s positioning in the competitive oncology imaging market and creating clearer pathways to value for shareholders.
More about TrivarX Limited
TrivarX Limited is an ASX-listed medical imaging and diagnostics company developing stable isotope-based platforms for cancer detection, with an initial focus on brain tumours. Its lead technology, Stabl-Im, aims to enhance MRI by enabling earlier, non-invasive identification of active tumour growth, positioning the company within the advanced imaging and radiopharmaceutical innovation segment.
YTD Price Performance: -15.79%
Average Trading Volume: 1,482,066
Technical Sentiment Signal: Sell
Current Market Cap: A$18.46M
Find detailed analytics on TRI stock on TipRanks’ Stock Analysis page.